Evidence map›Paper›PMID 29563785›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2018

Excess risk of major vascular diseases associated with airflow obstruction: a 9-year prospective study of 0.5 million Chinese adults.

Om P Kurmi, Liming Li, Kourtney J Davis, Jenny Wang, Derrick A Bennett, Ka Hung Chan, Ling Yang, Yiping Chen, Yu Guo, Zheng Bian and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. A Narrative Review of the Correlation Between Comorbidity and Acute Exacerbation of COPD Patients.International journal of chronic obstructive pulmonary disease · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Om P KurmiClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Liming LiDepartment of Epidemiology, School of Public Health, Peking University Health Science Center, Beijing, China.
Kourtney J DavisReal World Evidence and Epidemiology, GlaxoSmithKline, Collegeville, PA, USA.
Jenny WangClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Derrick A BennettClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ka Hung ChanClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ling YangClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yiping ChenClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yu GuoChinese Academy of Medical Sciences, Beijing China.
Zheng BianChinese Academy of Medical Sciences, Beijing China.
Junshi ChenChina National Center for Food Safety Risk Assessment, Beijing, China.
Liuping WeiNCDs Prevention and Control Department, Liuzhou CDC, Liuzhou, China.
Donghui JinNCDs Prevention and Control Department, Hunan CDC, Changsha, China.
Rory CollinsClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Richard PetoClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Zhengming ChenClinical Trial Service and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
University of Oxford · GBChinese Academy of Medical Sciences & Peking Union Medical College · CNChina National Center for Food Safety Risk Assessment · CNGlaxoSmithKline (United States) · USHunan Provincial Center for Disease Control and Prevention · CNLiu Zhou Center for Disease Prevention and Control · CNPeking University · CN

Funding

British Heart FoundationMedical Research Council MC_U137686851Medical Research Council MC_UU_12026/2Wellcome Trust 088158/Z/09/ZWellcome Trust 104085/Z/14/ZWellcome Trust 202922/Z/16/ZWellcome Trust 212946/Z/18/Z
6 · The paper itself

Abstract

Background: China has high COPD rates, even among never-regular smokers. Little is known about nonrespiratory disease risks, especially vascular morbidity and mortality after developing airflow obstruction (AFO) in Chinese adults. Objective: We aimed to investigate the prospective association of prevalent AFO with major vascular morbidity and mortality. Materials and methods: In 2004-2008, a nationwide prospective cohort study recruited 512,891 men and women aged 30-79 years from 10 diverse localities across China, tracking cause-specific mortality and coded episodes of hospitalization for 9 years. Cox regression yielded adjusted HRs for vascular diseases comparing individuals with spirometry-defined prevalent AFO at baseline to those without. Results: Of 489,382 participants with no vascular disease at baseline, 6.8% had AFO, with prevalence rising steeply with age. Individuals with prevalent AFO had significantly increased vascular mortality (n=1,429, adjusted HR 1.29, 95% CI 1.21-1.36). There were also increased risks of hemorrhagic stroke (n=823, HR 1.18, 95% CI 1.09-1.27), major coronary events (n=635, HR 1.33, 95% CI 1.22-1.45), and heart failure (n=543, HR 2.19, 95% CI 1.98-2.41). For each outcome, the risk increased progressively with increasing COPD severity and persisted among never-regular smokers. Conclusion: Among adult Chinese, AFO was associated with significantly increased risks of major vascular morbidity and mortality. COPD management should be integrated with vascular disease prevention and treatment programs to improve long-term prognosis.

Indexed as

AdultAgedAirway ObstructionCardiovascular DiseasesChinaChi-Square DistributionComorbidityForced Expiratory VolumeHumansLungMiddle AgedPrevalencePrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveChinachronic obstructive pulmonary diseasecohortexacerbationvascular diseases

Identifiers

PMID29563785
PMCPMC5846305
OpenAlexW2794312975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.